Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Inclusion Criteria

• •1. ≥ 18 years of age.
• •2. Diagnosis of CLL or SLL.
• •3. Received at least one prior anti-cancer therapy for CLL or SLL.
• •4. Previous exposure to BTKi and meet at least one of the criteria below:
• •1. Progressive disease (PD) while receiving or within 6 months after completing BTKi therapy.
• •2. Discontinued a BTKi therapy due to BTKi treatment- related intolerance.
• •5. Measurable disease with a lymph node or tumor mass \> 1.5 cm in at least one dimension.
• •6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• •7. Resolution of toxicities due to prior BTKi therapy to acceptable level.
• •8. Willingness of male and female patients to use medically acceptable methods of birth control.
• •9. Willing and able to participate in all required study evaluations and procedures.